Literature DB >> 2795285

Acute rejection and coronary artery disease in long-term survivors of heart transplantation.

J Narrod1, R Kormos, J Armitage, R Hardesty, J Ladowski, B Griffith.   

Abstract

The development of acute rejection and coronary artery disease (CAD) was studied in 173 patients who survived at least 1 year after orthotopic heart transplantation. There were 20 late deaths. The incidence of acute rejection found on endomyocardial biopsies after 1 year was 5.6%. Alteration in the immunosuppressive regimen accounted for 77% of the rejection episodes (chi-square = 9.3, F less than 0.01). Acute rejection without alteration in immunosuppressive therapy occurred only 1.4% of the time. CAD developed in 28 patients (16.2%). The prevalence of CAD was 5.8% at 1 year, 15.5% at 2 years, and increased to 66% at 6 years. Patients developing CAD had 0.5 (+/- 0.8) rejection episodes after 1 year as opposed to 0.2 (+/- 0.5) rejection episodes in patients with no CAD (S1 less than 0.01 by Mann-Whitney). There was no difference in the number of rejection episodes during the first year. The total number of rejection episodes was 1.9 (+/- 1.6) and 1.2 (+/- 1.2) in patients with and without CAD, respectively (S1 less than 0.03 by Mann-Whitney). Diabetes mellitus was present in 25% of patients with CAD and 16.5% of patients without CAD (chi-square = 3.14, F less than 0.1). Acute rejection rarely occurs after 1 year and is usually caused by an alteration in the immunosuppressive regimen. CAD develops with increasing frequency and is correlated with rejection episodes and diabetes mellitus.

Entities:  

Mesh:

Year:  1989        PMID: 2795285

Source DB:  PubMed          Journal:  J Heart Transplant        ISSN: 0887-2570


  9 in total

1.  Coronary artery disease after heart transplantation: clinical aspects.

Authors:  C D Scott; J H Dark
Journal:  Br Heart J       Date:  1992-09

2.  The Man with 2 Hearts: 25 Years from Heterotopic to Orthotopic Heart Transplantation.

Authors:  Elizabeth L Godfrey; Michael L Kueht; Abbas Rana; O H Frazier
Journal:  Tex Heart Inst J       Date:  2019-06-01

Review 3.  VLA-4 and lymphocyte trafficking in immune-inflammatory states: novel therapeutic approaches in allograft arteriopathy.

Authors:  S Molossi; M Rabinovitch
Journal:  Springer Semin Immunopathol       Date:  1995

4.  Coronary occlusive disease and late graft failure after cardiac transplantation.

Authors:  P A Mullins; N R Cary; L Sharples; J Scott; D Aravot; S R Large; J Wallwork; P M Schofield
Journal:  Br Heart J       Date:  1992-09

5.  Impairment of coronary flow reserve in orthotopic cardiac transplant recipients with minor coronary occlusive disease.

Authors:  P A Mullins; A Chauhan; L Sharples; N R Cary; S R Large; J Wallwork; P M Schofield
Journal:  Br Heart J       Date:  1992-09

6.  The development of transplant coronary artery disease after cardiac transplantation is correlated with a predominance of CD8+ T lymphocytes in endomyocardial biopsy derived T cell cultures.

Authors:  N H Jutte; K Groeneveld; A H Balk; A J Ouwehand; E H Loonen; M Van der Linden; S Strikwerda; B Mochtar; F H Claas; W Weimar
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

7.  Combined heart and liver transplant attenuates cardiac allograft vasculopathy compared with isolated heart transplantation.

Authors:  Yan Topilsky; Eugenia Raichlin; Tal Hasin; Barry A Boilson; John A Schirger; Naveen L Pereira; Brooks S Edwards; Alfredo L Clavell; Richard J Rodeheffer; Robert P Frantz; Manish J Gandhi; Simon Maltais; Soon J Park; Richard C Daly; Amir Lerman; Sudhir S Kushwaha
Journal:  Transplantation       Date:  2013-03-27       Impact factor: 4.939

8.  Perforin mediates endothelial cell death and resultant transplant vascular disease in cardiac allografts.

Authors:  Jonathan C Choy; Alexandra Kerjner; Brian W Wong; Bruce M McManus; David J Granville
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

9.  Modification of alternative messenger RNA splicing of fibroblast growth factor receptors in human cardiac allografts during rejection.

Authors:  X M Zhao; W H Frist; T K Yeoh; G G Miller
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.